BioPorto is pleased to announce the release of a new technical and clinical validation report
on BioPorto’s Monkey NGAL ELISA Kit.
The report, created by the Predictive Safety Testing Consortium (PSTC) Nephrotoxicity Working Group, which has evaluated precision, linearity, sample stability as well as physiological levels of NGAL in naïve monkeys, using BioPorto Diagnostics Monkey NGAL ELISA Kit and antibodies.
Predictive Safety Testing Consortium (PSTC)
created by the Critical Path Institute, is a neutral ground where scientists from 16 pharmaceutical companies and academia can share and test new methods that are more reliable predictors of human safety. The ultimate goal is to develop sufficient evidence to qualify new predictive safety tests for regulatory use that may improve the safety of new drugs that reach the market.
The kidney biomarker, NGAL, has repeatedly shown to be an important indicator of nephrotoxicity in a variety of laboratory animal models. BioPorto offers tools for measuring NGAL in mouse, rat, dog, pig and monkey sample material.
With this report, PSTC acknowledges the usefulness of BioPorto's Monkey NGAL ELISA Kit for non-clinical safety studies.